Citations

Clear

1446 citation(s) found for "Howard, F".

N0937(Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC).
Moreno‐Aspitia, Alvaro , Liu, Heshan , Rowland, Kendrith M. , Geiger, Xochiquetzal J., Stella, Philip J., Kourlas, Peter J., Gross, Howard M., Karlin, Nina J. , Bury, Martin J., Soori, Gamini S. , Perez, Edith A. , Hillman, David W. , Nassar, Aziza

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 1059-1059

10.1200/jco.2013.31.15_suppl.1059 Get It

1059 Background: Relapsed TNBC is characterized by its poor prognosis. B is a synthetic DNA minor groove binding non-cross resistant agent that is fully active against DNA-mismatch repair deficient tumor cells. C increases GSH/GST in which enhances the efficacy of B. Methods: Phase II study in pts with mTNBC. C Day 1 followed by B Day 2, repeated every 21 days. Aim: Efficacy of C + B in mTNBC. Primary endpoint: PFS at 3 mo. Secondary endpoints include ORR, duration of response (DOR), 6-mo PFS, OS and AE profile. Tertiary endpoints include assessment of baseline GSH levels, prevalence of BCRA1 mutation and pERK, and correlations with outcome. Results: Closed 3/2012. 48 pts accrued (1 ineligible pt). Median f/u 11.4 mo (6.6-14.8); 2 pts still on treatment. 47 pts evaluable for the PFS endpoint and AEs. 49% received therapy as 3rd-5th line. Median number of cycles = 4 (range 1-15). There are currently 9 confirmed responses (8 PR and 1 CR); DOR = 2.6-14.5 mo. The 3-mo PFS = 51%; 6-mo PFS = 28%; the median TTP is 3.2 mo. AE data: 75% G3/4 hematologic AE: febrile neutropenia 19%. Non-hematologic AEs included G3 (47%) and G4 (15%): G3 fatigue 17%; and no G5 non-heme AE. No correlation of GSH/GST levels with outcome was found. Among 35 pts with evaluable data, no association between BRCA1 expression and outcomes was found. pERK expression was negatively associated with 3-mo PFS, but not 6-mo PFS. Cytoplasmic pERK expression was negatively associated with tumor response (p=0.03). No significant effect of BRCA-1 or pERK expression was found on OS. Conclusions: This trial showed B + C is an active regimen, especially in heavily pretreated mTNBC pts. Correlative data demonstrated a negative association between pERK expression and outcomes. A randomized phase II trial is in development. Clinical trial information: NCT01091454.
Race- and health-related quality of life among patients newly diagnosed with multiple myeloma.
Durie, Brian G.M. , Rifkin, Robert M. , Abonour, Rafat , Gasparetto, Cristina, Mehta, Jayesh, Narang, Mohit , Shah, Jatin J., Terebelo, Howard R. , Thomas, Sachdev , Toomey, Kathleen, Swern, Arlene S., Harding, Gale, Sullivan, Kristen , Street, Thomas K., Khan, Zeba M., Pashos, Chris Leo , Fonseca, Rafaël , Gasparetto, Cristina

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: e18556-e18556

10.1200/jco.2012.30.15_suppl.e18556 Get It

e18556 Background: Studies in the United States (US) have identified variation in incidence and survival of multiple myeloma (MM) patients of different races, and noted that MM is the most common hematologic cancer among African Americans. This analysis evaluated whether health-related quality of life (HRQOL) of patients in the US varies by race as they initiate treatment having been newly diagnosed with active, symptomatic MM. Methods: Data were collected in Connect MM, a prospective US observational registry begun in September 2009. Data on patient demographics and clinical characteristics were provided by clinicians. HRQOL was reported by patients at enrollment within 2 months of diagnosis. Patients completed the Brief Pain Inventory (BPI), EQ-5D, and Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM). Mean reported scores for BPI, EQ-5D and FACT-MM were analyzed by patient race. Statistical significance was ascertained by ANOVA using SAS 9.1. Results: Baseline HRQOL data were reported by 1144 patients (enrolled in 228 centers) of whom 82% were White, 13% Black, and 6% Other race. The cohorts did not differ statistically by ECOG status or by multiple myeloma stage (assessed by either the International Staging System or the Durie and Salmon system). Compared to non-Blacks, Black patients reported less anxiety/depression on the EQ-5D (p=0.030) and better emotional well-being on the FACT-MM (p=0.003). No other statistically significant differences were noted between cohorts on the BPI, other EQ-5D domains (mobility, self care, usual activities, pain/discomfort), or other FACT-MM domains (physical, social/family, functional, and MM-specific considerations). Conclusions: Initial results from the Connect MM Registry indicate that baseline HRQOL prior to initiation of treatment may vary by patient race with respect to emotional well-being, and specifically anxiety/depression. These results serve as a baseline reference for future analyses. As patients in the Connect MM Registry proceed through therapy, analyses should be conducted of patients by race, among other characteristics and factors, to determine whether it may be associated with subsequent clinical outcomes and HRQOL over time.
Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group
Ansell, Stephen M. , Geyer, Susan M. , Kurtin, Paul J. , Inwards, David J. , Flynn, Patrick J. , Morton, Roscoe F., Luyun, Ronnie F., Dakhil, Shaker R. , Gross, Howard M., Kaufmann, Scott H. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | March 9, 2020 | Volume: 24 | Issue: 18_suppl | Pages: 7532-7532

10.1200/jco.2006.24.18_suppl.7532 Get It

7532 Background: Mantle Cell Lymphoma (MCL) is characterized by t(11;14) resulting in over expression of cyclin D1, a member of the phosphatidylinosital 3-kinase (PI3K) pathway. Temsirolimus is a novel inhibitor of the mammalian target of rapamycin (mTOR) kinase. Previous studies with weekly temsirolimus at a dose of 250mg demonstrated a 38% overall response rate in 35 patients (JCO 23 (23); 5347–56, 2005). Thrombocytopenia was frequently observed and was dose limiting. The current study tested whether low-doses (25mg) of temsirolimus could produce a similar overall response rate (ORR) with less toxicity. Methods: Eligible patients had biopsy proven cyclin D1 positive MCL and had relapsed or were refractory to therapy. Patients received temsirolimus 25mg IV weekly as a single agent. Patients were restaged after 1 cycle (4 doses), after 3 cycles, and every 3 cycles thereafter. Patients with a tumor response after 6 cycles were eligible to continue drug for a total of 12 or 2 cycles after complete remission (CR) and then were observed without maintenance. The goal was to achieve an ORR of at least 20%. Results: Twenty-nine patients were enrolled between March and August 2005. Twenty-two patients have completed therapy. One patient with a major protocol violation on cycle-1 and one ineligible patient were excluded, leaving 27 evaluable patients. The ORR was 41% (11/27), with 1 CR and 10 PRs. Early evaluation of TTP showed a median of 5.5 months (95% CI: 3.3–7.7) and the duration of response for the 11 responders was 6.2 months (95% CI: 3.6 to not yet reached). These results compare favorably with the 6.5 months and 6.9 months, respectively, found in previous trials that used 250 mg. The median dose delivered per month was 80 mg (range, 10–100 mg). Sixteen (59%) of patients required a dose reduction. The median time on treatment was 4.4 months (95% CI, 3.3–7.7). The incidence of grade 3 and 4 thrombocytopenia was 12% and 0%, respectively. One patient experienced grade 5 infection without neutropenia, which was considered unrelated to CCI-779. Conclusions: Single agent CCI-779 at a dose of 25mg has anti-tumor activity in relapsed MCL similar to the 250 mg dose. This study indicates that combinations of temsirolimus with other agents should be feasible. [Table: see text]
Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB)
Jatoi, Aminah , Rowland, K. M., Sloan, Jeff A. , Gross, Howard M., Fishkin, Paul A. S., Kahanic, Stephen P., Novotny, Paul J. , Schaefer, Paul, Dakhil, Shaker R. , Loprinzi, Charles L.

Mayo Clinic

Journal of Clinical Oncology | March 6, 2020 | Volume: 25 | Issue: 18_suppl | Pages: LBA9006-LBA9006

10.1200/jco.2007.25.18_suppl.lba9006 Get It

LBA9006 Purpose: Many patients who receive EGFR inhibitors develop an acneiform rash, and anecdotal reports suggest tetracycline is effective in treating it. To our knowledge, however, no rigorous trials have ever been published to substantiate this approach. This double- blinded, placebo-controlled trial was conducted to assess the role of tetracycline in preventing EGFR inhibitor-induced rash and/or reducing its severity. Methods: 61 patients were randomly assigned to tetracycline 500 mg orally twice a day×4 weeks versus an identical, similarly prescribed placebo. Eligibility criteria required all patients to have begun an EGFR inhibitor </= 7 days prior with no rash at study entry. Patients were to be followed for 8 weeks. Physician assessments of rash incidence, severity, and adverse events, occurred at 4 and 8 weeks. Patients completed a weekly rash diary, quality of life questionnaire (SKINDEX-16), and EGFR inhibitor compliance questionnaire. Thirty patients per group provides 90% power to detect a difference in rash incidence (the primary endpoint) of 40% between groups and of rejecting the null hypothesis of equal proportions with a type I error of 5% (2-sided). Results: Treatment arms were balanced on baseline characteristics, drop out rates, and rates of discontinuation of the EGFR inhibitor. Rash incidence was comparable across arms. Physicians reported that 16 tetracycline-treated patients (70%) and 22 placebo-exposed patients (76%) developed a rash (p=0.61). However, tetracycline appears to have lessened rash severity. By week 4, physician-reported grade 2 rash occurred in 17% of tetracycline-treated patients (n=4) and 55% of placebo- exposed patients (n=16); (p=0.04). Tetracycline-treated patients reported better scores on certain quality of life parameters (SKINDEX-16), such as skin burning or stinging, skin irritation, and being bothered by a persistence/recurrence of a skin condition. Adverse events were comparable across arms. Conclusion: Tetracycline did not prevent EGFR inhibitor-induced rashes. However, diminished rash severity and improved quality of life suggest this antibiotic merits further study. No significant financial relationships to disclose.
Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T)
Antelo, Guadalupe Belen, Mangaonkar, Abhishek A. , Coltro, Giacomo , Buradkar, Ajinkya , Finke, Christy M. , Binder, Moritz , Gangat, Naseema , Al‐Kali, Aref , Elliott, Michelle A. , King, Rebecca L. , Howard, Matthew T., Melody, Megan , Litzow, Mark R. , Tefferi, Ayalew , Fernández-Zapico, Martín E. , Komrokji, Rami S. , Patnaik, Mrinal M. , Antelo, Guadalupe, Lasho, Terra L. , Carr, Ryan, Binder, Moritz , Al-Kali, Aref , Howard, Matthew, Hogan, William, Tefferi, Ayalew , Komrokji, Rami S , Carr, Ryan M , Hogan, William J.

Mayo Clinic

British Journal of Haematology | March 4, 2020 | Volume: 189 | Issue: 3 | Pages: No page available

10.1111/bjh.16515 | PMID 32128785 Get It

A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415.
Khairnar, Rahul , DeMora, Lyudmila, Olives, Ester Villalonga , Shah, Amit , Malone, Shawn , Michalski, Jeff M. , Dayes, Ian S. , Albert, Michele, Pisansky, Thomas M. , Chen, Yuhchyau , Horwitz, Eric M. , DeNittis, Albert S., Feng, Felix Y. , Dayes, Ian S , Sandler, Howard M. , Lee, W. Robert , Mullins, C. Daniel , Bruner, Deborah Watkins , Seaward, Samantha A , Currey, Adam D. , Mishra, Mark V.

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 55-55

10.1200/jco.2020.38.6_suppl.55 Get It

55 Background: To compare the predictive ability of health utility mapping algorithms derived using cross-sectional and longitudinal data specific to the Expanded Prostate Cancer Index Composite (EPIC). Methods: This mapping study utilized data from an international, multicenter, randomized controlled trial of patients with low-risk prostate cancer conducted by NRG Oncology (NCT00331773). Health-related quality-of-life (HRQoL) data were collected using EPIC, and health utilities were obtained using EuroQOL-5D (EQ5D) at baseline and 6, 12 and 24 months post-intervention. Data were split into an estimation sample (70%) and a validation sample (30%). Ordinary Least Squares (OLS) regression models were estimated using baseline cross-sectional data as well as pooled data from all assessment periods. Random effects (RE) specifications that explicitly model the longitudinal nature of the data were also estimated. Candidate models were selected based on root mean square error (RMSE). Results: A total of 196 (147) patients in the estimation sample had complete EQ5D and EPIC domain (subdomain) data at all time points. OLS models using combined data outperformed the counter-part RE models as well as OLS models using baseline data in the five-fold cross-validation. Addition of covariates to the models resulted in improved predictive ability. In the external validation, when only EPIC domain/ subdomain data are available, the OLS model using combined data predicted EQ5D utilities better than the counterpart RE model and OLS model using baseline data (RMSE=0.121108 & 0.111345). OLS model using baseline data outperformed other model types for algorithms with EPIC domains and demographics (RMSE=0.121757), while RE models outperformed the other two model types for algorithms with EPIC subdomains and demographic data, (0.112782) and for algorithms with EPIC domains/ subdomains, demographics, and clinical covariates (RMSE=0.123589 & 0.163093). Conclusions: While algorithms using pooled data outperformed other model types in internal validation, RE models showed better predictive ability in external validation for algorithms with covariates. Clinical trial information: NCT00331773.
Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.
Kishan, Amar U. , Romero, Tahmineh , Garraway, Isla P. , Roach, Mack , Pisansky, Thomas M. , Michalski, Jeff M. , Jones, Christopher U. , Feng, Felix Y. , Nickols, Nicholas G. , Mahal, Brandon A. , Dess, Robert T. , Steinberg, Michael L. , Elashoff, David , Dess, Robert T , Rettig, Matthew B. , Lee, W. Robert , Rosenthal, Seth A. , Boutros, Paul C. , Tran, Phuoc T , Sandler, Howard M. , Spratt, Daniel E.

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 327-327

10.1200/jco.2020.38.6_suppl.327 Get It

327 Background: Though Black men with prostate cancer are more likely to have aggressive disease features than White men, race-specific differences in initial treatment responses in localized disease remains unknown. Methods: Individual patient data were obtained for 9259 patients (including 1674 [18.1%] Black men and 7585 [81.9%] White men) enrolled on eight randomized controlled trials evaluating definitive radiotherapy (RT) ± short-term or long-term androgen deprivation therapy (STADT and LTADT). The primary endpoints were biochemical recurrence (BCR), distant metastasis (DM), and prostate cancer-specific mortality (PCSM). Fine-Gray subdistribution HR (sHR) models were developed to evaluate the cumulative incidences of all endpoints after stratification by National Comprehensive Cancer Network risk grouping. A meta-analysis was done to estimate pair-wise comparisons of treatments within and between Black and White men, after adjusting for age, Gleason score, clinical T stage, and initial PSA. Results: Black men were more likely to have NCCN high-risk disease at enrollment (656/1674 [39.2%] vs 2506/7585 [33%], p<0.001). However, within the high-risk stratum Black men had lower 10-year rates of BCR (46.1% vs. 50.4%, p=0.02), DM (14% vs. 21.6%, p<0.001), and PCSM (4.9% vs. 9.8%, p<0.001). After adjusting for age and disease characteristics, Black men with high-risk prostate receiving RT+STADT had lower rates of BCR (sHR 0.73, 95% CI 0.62-0.86, p<0.001), DM (sHR 0.64, 95% CI 0.49-0.84, p=0.001) and PCSM (sHR 0.49, 95% CI 0.25-0.95, p=0.04). There were no differences in BCR, DM, or PCSM among men receiving RT+LTADT. The interaction between race and the impact of adding STADT to RT alone on BCR was statistically significant (p=0.003). Conclusions: Black men enrolled on randomized trials with long-term follow-up have higher risk disease at enrollment, but have better BCR, DM, and PCSM outcomes with RT-based therapy compared with White men, particularly with the addition of STADT.
Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.
Feng, Felix Y. , Huang, Huei–Chung, Simko, Jeffry, Dignam, James J., Seiferheld, Wendy, Lukka, Himanshu, Bahary, Jean-Paul , Pisansky, Thomas M. , Hall, William A. , Shah, Amit I., Pugh, Stephanie L. , Pollack, Alan , Shipley, William U. , Sandler, Howard M. , Davicioni, Elai , Nguyen, Paul L. , Efstathiou, Jason A. , Dicker, Adam P. , Spratt, Daniel E. , Tran, Phuoc T

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 276-276

10.1200/jco.2020.38.6_suppl.276 Get It

276 Background: Decipher is a genomic classifier (GC) that estimates risk of prostate cancer (PCa) distant metastases (DM) post-radical prostatectomy (RP). Herein, we validate the GC within the context of a randomized phase 3 trial. Methods: RP specimens from patients on the NRG/RTOG 9601 phase 3 placebo-controlled randomized trial of salvage radiotherapy (sRT) +/- 2 years of bicalutamide (NCT00002874) were centrally reviewed and the highest-grade tumor underwent RNA extraction. Samples passing quality control (QC) were run on a clinical-grade whole-transcriptome assay to assign the GC score (scale 0-1). Our NCTN-CCSC approved pre-specified statistical plan (NRG-GU-TS002 CSC0075) included the primary objective of validating the ability of the GC to independently prognosticate the cumulative incidence of DM, with secondary endpoints of prostate cancer-specific mortality (PCSM) and overall survival (OS). Results: Of patients with tissue available, 352 passed QC and were included for analysis. The final GC cohort was a representative sample of the overall cohort, with a median follow-up of 13 years. On multivariable analysis, the GC (continuous variable) was independently associated with DM (HR 1.19 [95%CI 1.06-1.35], p=0.003), PCSM (HR 1.37 [95%CI 1.18-1.61], p<0.001), and OS (HR 1.16 [95%CI 1.06-1.28], p=0.002) after adjusting for age, race, Gleason score, T-stage, margin status, entry PSA, and treatment arm. The estimated absolute impact of bicalutamide on 12-year OS was less in patients with lower vs higher GC scores (2.4% vs 8.9%), further demonstrated in men receiving early sRT at PSA <0.7 ng/mL (-2.0% vs 5.0%). Conclusions: This is the first validation of this GC in a prospective randomized trial cohort and demonstrates association of the GC with DM and PCSM independent of standard clinicopathologic variables. The GC may help personalize shared decision-making to weigh the absolute benefit from the addition of bicalutamide to sRT.
Novel congenital disorder of O -linked glycosylation caused by GALNT2 loss of function
Zilmer, Monica , Edmondson, Andrew C. , Khetarpal, Sumeet A. , Alesi, Viola , Zaki, Maha S. , Rostásy, Kevin , Madsen, Charlotte , Lepri, Francesca Romana , Sinibaldi, Lorenzo , Novelli, Antonio , Issa, Mahmoud Y. , Fenger, Christina , Agolini, Emanuele , Petäjä‐Repo, Ulla E. , Hintze, John , Raymond, Kimiyo , Liedtke, Kristen, Stanley, Valentina , Musaev, Damir, Gleeson, Joseph G. , Vitali, Cecilia , Rubboli, Guido , Schjoldager, Katrine T. , Møller, Rikke S. , Raymond, Kimiyo M, Agolini, Emanuele , Rubboli, Guido , Edmondson, Andrew C , Møller, Rikke S , Madsen, Camilla G, Cusmai, Raffaella , Jamra, Rami Abou , Reutter, Heiko , Briuglia, Silvana , Hansen, Lars Hestbjerg , Stanley, Valentina , Gleeson, Joseph G. , O’Brien, W Timothy, Gardella, Elena , Rader, Daniel J

Mayo Clinic

Brain | February 17, 2020 | Volume: 143 | Issue: 4 | Pages: 1114-1126

10.1093/brain/awaa063 | PMID 32293671 Get It

Abstract Congenital disorders of glycosylation are a growing group of rare genetic disorders caused by deficient protein and lipid glycosylation. Here, we report the clinical, biochemical, and molecular features of seven patients from four families with GALNT2-congenital disorder of glycosylation (GALNT2-CDG), an O-linked glycosylation disorder. GALNT2 encodes the Golgi-localized polypeptide N-acetyl-d-galactosamine-transferase 2 isoenzyme. GALNT2 is widely expressed in most cell types and directs initiation of mucin-type protein O-glycosylation. All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant substrate for GALNT2. Patients with GALNT2-CDG generally exhibit a syndrome characterized by global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features, decreased stature, and decreased high density lipoprotein cholesterol levels. Rodent (mouse and rat) models of GALNT2-CDG recapitulated much of the human phenotype, including poor growth and neurodevelopmental abnormalities. In behavioural studies, GALNT2-CDG mice demonstrated cerebellar motor deficits, decreased sociability, and impaired sensory integration and processing. The multisystem nature of phenotypes in patients and rodent models of GALNT2-CDG suggest that there are multiple non-redundant protein substrates of GALNT2 in various tissues, including brain, which are critical to normal growth and development.
Shared genetic risk between eating disorder‐ and substance‐use‐related phenotypes: Evidence from genome‐wide association studies
Munn‐Chernoff, Melissa A. , Chou, Yi‐Ling, Coleman, Jonathan R. I. , Thornton, Laura M. , Walters, Raymond K. , Yılmaz, Zeynep , Baker, Jessica H. , Hübel, Christopher , Medland, Sarah E. , Hinney, Anke , Leppä, Virpi , Mattheisen, Manuel , Ripke, Stephan , Yao, Shuyang , Giusti‐Rodríguez, Paola , Hanscombe, Ken B. , Adan, Roger A.H. , Ando, Tetsuya , Berrettini, Wade H., Boehm, Ilka , Boni, Claudette, Perica, Vesna Boraska , Buehren, Katharina, Burghardt, Roland , Cassina, Matteo , Cichon, Sven , Clementi, Maurizio , Courtet, Philippe, Crowley, James J. , Danner, Unna N. , Davis, Oliver S. P. , Zwaan, Martina de, Degortes, Daniela, DeSocio, Janiece E., Dick, Danielle M., Dikeos, Dimitris, Dina, Christian , Dmitrzak‐Węglarz, Monika , Docampo, Elisa, Duncan, Laramie E. , Egberts, Karin , Ehrlich, Stefan , Escaramís, Geòrgia, Estivill, Xavier , Farmer, Anne, Favaro, Angela , Fernández‐Aranda, Fernando , Fichter, Manfred M., Fischer, Krista , Föcker, Manuel , Foretová, Lenka , Forstner, Andreas J. , Franklin, Christopher S., Gallinger, Steven , Giegling, Ina , Giuranna, Johanna, Gonidakis, Fragiskos , Gorwood, Philip , Mayora, Monica Gratacos, Guo, Yiran , Håkonarson, Håkon , Hatzikotoulas, Konstantinos , Hebebrand, Johannes , Helder, Sietske G., Herpertz‐Dahlmann, Beate, Herzog, Wolfgang , Huckins, Laura M. , Hudson, James I. , Imgart, Hartmut , Inoko, Hidetoshi , Janout, Vladimí­r , Jiménez‐Múrcia, Susana , Kalsi, Gursharan , Kaminská, Deborah , Karwautz, Andreas , Kas, Martien J. , Keski‐Rahkonen, Anna , Kiezebrink, Kirsty , Kim, Youl‐Ri , Klump, Kelly L. , Knudsen, Gun Peggy , Via, Maria C. La, Hellard, Stéphanie Le , Levitan, Robert D., Lilenfeld, Lisa , Lin, Bochao , Lissowska, Jolanta , Luykx, Jurjen J. , Magistretti, Pierre J. , Maj, Mario , Männik, Katrin , Marsal, Sara , Marshall, Christian R. , McDevitt, Sara , McGuffin, Peter, Meulenbelt, Ingrid, Navratilova, Marie, Ντάλλα, Ιωάννα , O’Toole, Julie K., Padyukov, Leonid , Palotie, Aarno , Pantel, Jacques , Papežová, Hana , Pinto, Dalila , Rabionet, Raquel , Raevuori, Anu , Ramoz, Nicolás , Reichborn‐Kjennerud, Ted , Ricca, Valdo , Ritschel, Franziska , Roberts, Marion, Rotondo, Alessandro, Rujescu, Dan, Rybakowski, Filip , Scherer, Stephen W. , Schmidt, Ulrike , Schork, Nicholas J. , Schosser, Alexandra , Šlachtová, Lenka , Landt, M , Slopien, Agnieszka, Sorbi, Sandro , Świątkowska, Beata , Szatkiewicz, Jin P., Tachmazidou, Ioanna, Tenconi, Elena, Tortorella, Alfonso , Tozzi, Federica, Treasure, Janet , Tziouvas, Konstantinos , Elburg, Annemarie , Furth, Eric F. van , Wagner, Gudrun , Walton, Esther , Widén, Elisabeth , Zerwas, Stephanie , Zipfel, Stephan, Bergen, Andrew W. , Brandt, Harry, Crawford, Steven , Halmi, Katherine A. , Johnson, Craig, Kaplan, Allan S. , Kaye, Walter H. , Mitchell, James E. , Olsen, Catherine M. , Pedersen, Nancy L. , Strober, Michael, Whiteman, David C. , Woodside, D. Blake , Grove, Jakob , Henders, Anjali K. , Larsen, Janne Tidselbak , Petersen, Liselotte , Jordan, Jennifer , Kennedy, Martin A. , Birgegård, Andreas , Landén, Mikael , Polimanti, Renato , McClintick, Jeanette N. , Adkins, Amy , Alıev, Fazil , Bacanu, Silviu‐Alin , Batzler, Anthony , Bertelsen, Sarah , Chen, Li‐Shiun , Degenhardt, Franziska , Docherty, Anna R. , Edwards, Alexis C. , Foo, Jerome C. , Fox, Louis , Frank, Josef , Hack, Laura M. , Hartmann, Annette M. , Hartz, Sarah M. , Hodgkinson, Colin A. , Hottenga, Jouke‐Jan, Konte, Bettina , Lahti, Jari , Lahti‐Pulkkinen, Marius , Ligthart, Lannie , Loukola, Anu , Maher, Brion S. , Mbarek, Hamdi , McIntosh, Andrew M. , McQueen, Matthew B. , Meyers, Jacquelyn L. , Milaneschi, Yuri , Palviainen, Teemu , Ryu, Euijung , Saccone, Nancy L. , Salvatore, Jessica E. , Streit, Fabian , Wang, Jen‐Chyong , Webb, Bradley T. , Wetherill, Leah , Wills, Amanda G. , Zhou, Hang , Boardman, Jason D., Chen, Danfeng , Copeland, William , Culverhouse, Robert , Dahmen, Norbert, Domingue, Benjamin W. , Frye, Mark A. , Gäebel, Wolfgang , Ising, Marcus, Keyes, Margaret A., Kiefer, Falk , Koller, Gabriele , Kuperman, Samuel , Lucae, Susanne , Lynskey, Michael T. , Maier, Wolfgang , Müller‐Myhsok, Bertram , Preuss, Ulrich W. , Räikkönen, Katri , Reynolds, Maureen , Ridinger, Monika , Schuckit, Marc A. , Soyka, Michael , Wodarz, Norbert , Zill, Peter , Adkins, Daniel E. , Bucholz, Kathleen K. , Diazgranados, Nancy , Goate, Alison , Goldman, David , Hancock, Dana B. , Hewitt, John K. , Johnson, Eric O. , Krauter, Kenneth , Lind, Penelope A. , McGue, Matt , MacKillop, James , Madden, Pamela A. F. , Maes, Hermine H. , Magnusson, Patrik K. E. , Nelson, Elliot C. , Nöthen, Markus M. , Penninx, Brenda W.J.H. , Porjesz, Bernice , Rice, John P. , Rose, Richard J. , Shen, Pei‐Hong , Silberg, Judy L. , Tarter, Ralph E. , Vrieze, Scott , Zhao, Hongyu , Neale, Benjamin M. , Wade, Tracey , Sullivan, Patrick F., Kaprio, Jaakko , Breen, Gerome , Hottenga, Jouke‐Jan , Hakonarson, Hakon , Lissowska, Jolanta , Kennedy, Martin A , Ehrlich, Stefan , Hottenga, Jouke-Jan , Walton, Esther , Cichon, Sven , Luykx, Jurjen J , Nöthen, Markus M , Le Hellard, Stephanie , Penninx, Brenda W J H , Medland, Sarah E , Rabionet, Raquel , Estivil, Xavier , Padyukov, Leonid , Świątkowska, Beata , Dina, Christian , Palotie, Aarno V. , Ripke, Stephan , Whiteman, David C , Scherer, Stephen W , Tortorella, Alfonso , Streit, Fabian , Egberts, Karin , Goate, Alison M , Docherty, Anna R , Johnson, Eric O , Coleman, Jonathan Ri , Johnson, Emma C. , Gordon, Scott D. , Watson, Hunna J. , Gaspar, Héléna A. , Bryois, Julien , Alfredsson, Lars , Andreassen, Ole A. , Boehm, Ilka , Cone, Roger D. , Courtet, Philippe , Crow, Scott J. , Dedoussis, George , Dick, Danielle M. , Dikeos, Dimitris , Escaramís, Geòrgia , Esko, Tõnu , Forzan, Monica , Guillaume, Sébastien , Hauser, Joanna , Herms, Stefan , Herpertz-Dahlmann, Beate , Julià, Antonio , Karhunen, Leila J. , Kennedy, James L. , Li, Dong , Mattingsdal, Morten , Metspalu, Andres , Micali, Nadia , Mitchell, Karen S. , Monteleone, Alessio Maria , Monteleone, Palmiero , Nacmias, Benedetta , Ophoff, Roel A. , Ripatti, Samuli , Roberts, Marion , Santonastaso, Paolo , Scherag, André , Seitz, Jochen , Slagboom, P. Eline , Tenconi, Elena , Τσίτσικα, Άρτεμις , Tyszkiewicz‐Nwafor, Marta , Zeggini, Eleftheria , Boden, Joseph M. , Horwood, L. John , Pearson, John F , Werge, Thomas Mears , Parker, Richard , Lichtenstein, Paul , Norring, Claes E. A. , Mortensen, Preben Bo , Biernacka, Joanna M. , Bigdeli, Tim B. , Clarke, Toni‐Kim , Heilmann‐Heimbach, Stefanie , Hoffmann, Per , Lai, Dongbing , Peterson, Roseann Elizabeth , Sanchez-Roige, Sandra , Schwandt, Melanie L. , Sherva, Richard , Strohmaier, Jana , Thomas, Nathaniel , Wedow, Robbee , Boardman, Jason D., Choi, Doo‐Sup , Degenhardt, Louisa J , Hayward, Caroline , Kramer, John R. , Mann, Karl F , Männistö, Satu , Murray, Alison D. , Nurnberger, John I , Scherbaum, Norbert , Treutlein, Jens , Witt, Stephanie H. , Boomsma, Dorret I , Bierut, Laura Jean , Brown, Sandra A. , Costello, E. Jane , Wit, Harriet de , Eriksson, Johan G. , Farrer, Lindsay A. , Foroud, Tatiana , Gillespie, Nathan A. , Grucza, Richard A. , Harris, Kathleen Mullan , HESSELBROCK, VICTOR M. , Hopfer, Christian Jean , Iacono, William G. , Karpyak, Victor M. , Kendler, Kenneth S. , Kranzler, Henry R. , Palmer, Abraham A. , Rietschel, Marcella , Riley, Brien P. , Stallings, Michael C. , Vanyukov, Michael M. , Wall, Tamara L. , Whitfield, John B. , Heath, Andrew C. , Montgomery, Grant W. , Martin, Nicholas G. , Gelernter, Joel E. , Edenberg, Howard J , Bulik, Cynthia Marie , Agrawal, Arpana , Webb, Bradley T. , Marshall, Christian R. , Crowley, James J.

Mayo Clinic

Addiction Biology | February 17, 2020 | Volume: 26 | Issue: 1 | Pages: No page available

10.1111/adb.12880 | PMID 32064741 Get It

Abstract Eating disorders and substance use disorders frequently co‐occur. Twin studies reveal shared genetic variance between liabilities to eating disorders and substance use, with the strongest associations between symptoms of bulimia nervosa and problem alcohol use (genetic correlation [ r g ], twin‐based = 0.23‐0.53). We estimated the genetic correlation between eating disorder and substance use and disorder phenotypes using data from genome‐wide association studies (GWAS). Four eating disorder phenotypes (anorexia nervosa [AN], AN with binge eating, AN without binge eating, and a bulimia nervosa factor score), and eight substance‐use‐related phenotypes (drinks per week, alcohol use disorder [AUD], smoking initiation, current smoking, cigarettes per day, nicotine dependence, cannabis initiation, and cannabis use disorder) from eight studies were included. Significant genetic correlations were adjusted for variants associated with major depressive disorder and schizophrenia. Total study sample sizes per phenotype ranged from ~2400 to ~537 000 individuals. We used linkage disequilibrium score regression to calculate single nucleotide polymorphism‐based genetic correlations between eating disorder‐ and substance‐use‐related phenotypes. Significant positive genetic associations emerged between AUD and AN ( r g = 0.18; false discovery rate q = 0.0006), cannabis initiation and AN ( r g = 0.23; q < 0.0001), and cannabis initiation and AN with binge eating ( r g = 0.27; q = 0.0016). Conversely, significant negative genetic correlations were observed between three nondiagnostic smoking phenotypes (smoking initiation, current smoking, and cigarettes per day) and AN without binge eating ( r gs = −0.19 to −0.23; qs < 0.04). The genetic correlation between AUD and AN was no longer significant after co‐varying for major depressive disorder loci. The patterns of association between eating disorder‐ and substance‐use‐related phenotypes highlights the potentially complex and substance‐specific relationships among these behaviors.